

Drug Monograph

Drug Name: **Aklief® (trifarotene) cream**
 Drug Class: **Topical Retinoid Agents**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Aklief 0.005% cream is available in a 45-gram pump. Each gram of Aklief cream contains 50 mcg of trifarotene in a white cream.

Manufacturer: Marketed by: Galderma Laboratories, L.P. Fort Worth, Texas 76177

Indications: Aklief cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Costs: \$554 per 46-gram pump Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Jennifer Anderson PharmD, BCPS
 Date: December 29, 2019